Skip to main content

Table 4 Correlations of change in selected outcome measures with drug exposure and reduction in plasma amyloid-β peptide 40 in the active arms a

From: Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer’s disease

 

Semagacestat AUC

Change in plasma Aβ40

AUC adjusted for Aβ40

Aβ40 adjusted for AUC

 

r

n

P

r

n

P

r

n

P

r

n

P

Change in uric acid at week 76

−0.151

320

0.007

0.011

263

0.857

−0.149

260

0.016

0.071

260

0.255

Change in albumin at week 76

−0.14

320

0.012

−0.131

263

0.033

−0.037

260

0.548

−0.107

260

0.084

Gastrointestinal symptoms

0.015

943

0.654

0.099

507

0.025

−0.004

501

0.933

0.094

501

0.034

Skin disorder incidence

0.016

943

0.627

0.083

507

0.062

−0.048

501

0.279

0.096

501

0.031

Skin cancer incidence

−0.012

943

0.71

0.075

507

0.091

−0.039

501

0.389

0.084

501

0.059

Infection incidence

0.136

943

<0.001

0.072

507

0.101

0.068

501

0.129

0.042

501

0.344

Annualized change in FDG SUVR

0.22

74

0.06

<0.001

48

0.998

0.357

48

0.010

−0.134

48

0.364

Annualized change in ventricular volume

0.003

139

0.97

0.242

91

0.021

−0.109

91

0.302

0.264

91

0.010

Annualized change in right hippocampal volume

−0.064

130

0.472

−0.264

86

0.014

−0.039

86

0.719

−0.222

86

0.038

Annualized change in left hippocampal volume

−0.109

130

0.216

−0.036

86

0.74

−0.167

86

0.123

0.043

86

0.697

Annualized change in AV45 SUVR

0.133

40

0.414

0.316

27

0.109

−0.079

27

0.697

0.324

27

0.093

Annualized change in ADASCog11

−0.012

938

0.707

0.037

505

0.403

−0.080

499

0.074

0.060

499

0.177

Annualized change in MMSE

0.038

618

0.351

−0.019

496

0.678

0.057

490

0.211

−0.037

490

0.414

Annualized change in p-tau

0.02

37

0.909

−0.124

33

0.491

0.101

33

0.578

−0.154

33

0.395

Annualized change in total tau

0.07

35

0.691

0.003

31

0.986

−0.017

31

0.930

0.010

31

0.957

Annualized change in CSF Aβ42

−0.13

37

0.443

0.152

33

0.399

−0.103

33

0.571

0.179

33

0.318

  1. aAβ40, Amyloid-β peptide 40; Aβ42, Amyloid-β peptide 42; ADAScog11, Alzheimer’s Disease Assessment Scale Cognitive Subscale, 11-item version; AUC, Area under the concentration curve; AV45, Florbetapir; CSF, Cerebrospinal fluid; FDG-PET, Fludeoxyglucose positron emission tomography; MMSE, Mini Mental State Examination; p-tau, Phosphorylated tau; SUVR, Standard uptake value ratio.